Risk factor
Negligible price volatility
Profitability factor
Excellent dividends
In Guru Portfolios
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
| Michael Burry | Scion Asset Management | 11.1% | +11.07% |
| Steven Cohen | Point72 Asset Management, L.P. | 0.1% | -0.14% |
| Kenneth Griffin | CITADEL ADVISORS LLC | 0.1% | -0.03% |
About
Pfizer Inc. operates as a global biopharmaceutical enterprise, actively involved in the discovery, innovation, manufacturing, promotion, distribution, and sale of its pharmaceutical portfolio across the United States, Europe, and numerous international markets. The company’s comprehensive product range encompasses medicines and vaccines for a wide spectrum of therapeutic areas. These include treatments for cardiovascular and metabolic conditions, migraines, and women's health, exemplified by brands such as Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family. Pfizer also addresses infectious diseases with products like the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba, alongside its contributions to COVID-19 prevention and treatment, featuring Comirnaty and Paxlovid, and ongoing efforts in mRNA and antiviral technologies. Further offerings include biosimilars for chronic immune and inflammatory disorders, represented by Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo; and specialized medications for conditions such as amyloidosis, hemophilia, endocrine diseases, and sickle cell disease, found under brands like the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin. The company also supplies sterile injectable and anti-infective medications, including Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga, in addition to a substantial oncology and specialty pipeline featuring biologics, small molecules, immunotherapies, and biosimilars like Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi. Additionally, Pfizer engages in contract manufacturing services. Its clientele is diverse, spanning wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical offices, and integrated healthcare delivery systems. The company maintains significant collaboration agreements with partners such as Bristol-Myers Squibb Company, Astellas Pharma US, Inc., Merck KGaA, and BioNTech SE. Pfizer Inc. was established in 1849 and has its corporate headquarters situated in New York, New York.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value
Target Price
The average target price of PFE is 29.5 and suggests 2.29% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation